



Contact:

Dr. Misha Plam, President and CEO

AmideBio, LLC

Misha.plam@amidebio.com

303 641 3669

AmideBio Selected to Present at the 2013 Rocky Mountain Life Science Investor and Partnering Conference in Denver (RMLIPC)

Boulder, CO. August 25, 2013– AmideBio, LLC announced today that Dr. Michael Stowell, Chief Technology Officer of AmideBio, will be presenting at The Rocky Mountain Life Science Investor and Partnering Conference, September 19, 2013 at the Ritz-Carlton in Denver, Colorado.

AmideBio's presentation will focus on its proprietary technology for the design and manufacturing of Novel Thermo and Fibrillation Stable Insulins for the Treatment of Diabetes. The company believes the combination of its proprietary BioPure™ manufacturing platform and rationally designed stable insulins has significant commercial potential in the rapidly growing insulin market that is expected to reach \$32 billion in annual sales by 2018.

RMLIPC received numerous applications from companies across Colorado and the four other States in the region to present at the 2013 Conference. After a rigorous screening process, AmideBio, LLC was selected along with the other top 30 regional companies that received invitations..

About AmideBio, LLC

AmideBio based in Boulder, CO is a biotechnology company focused on providing recombinant peptide research and clinical products for a diverse array of disease research and disease targets. AmideBio maintains a proprietary platform vector technology that addresses the challenges of historically difficult to manufacture peptides by providing products that are reliable (BioPure™), economical and incorporate environmentally sustainable practices. For more information please visit www.AmideBio.com

About the Rocky Mountain Life Science Investor & Partnering Conference

The 2013 Rocky Mountain Life Science Investor & Partnering Conference – spearheaded by the Colorado BioScience Association in collaboration with associations in Arizona, Montana, New Mexico and Utah — will open with a reception at the Colorado Governor's Mansion September 18th and follow with a full day of company pitch presentations September 19th. The keynote breakfast will include Kyle Lefkoff, founder and General Partner of Boulder Ventures, leading a conversation with the CEOs of Colorado's two premier publicly-traded pharmaceutical companies-Patrick Mahaffy, Founder and CEO of Clovis Oncology and Ron Squarer, CEO of Array BioPharma. The keynote lunch will be a presentation from Johnson & Johnson Development Corporation executive leadership. For more information and registration details, visit <http://www.RockyMtnBioInvest.com>.

About Colorado BioScience Association

The CBSA is a not-for-profit organization providing services and support for Colorado's bioscience industry. With more than 350 members, CBSA actively works to promote the growth of the industry by advocating for a better business environment, growing the state's biotech workforce, fighting for policies that support a strong bioscience industry in the state, and speaking with a single voice on behalf of the industry. For more information, visit <http://www.cobioscience.com>.